ClearPoint Neuro (NASDAQ:CLPT) Issues Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) issued its quarterly earnings data on Monday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.09), FiscalAI reports. The firm had revenue of $10.88 million for the quarter, compared to the consensus estimate of $12.73 million. ClearPoint Neuro had a negative return on equity of 165.29% and a negative net margin of 81.76%.During the same period in the prior year, the company posted ($0.21) earnings per share.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• Q2 revenue increased 18% year over year to $10.9 million, helped by IRRAflow, higher operating-room procedural volumes, and increased placement of ClearPoint, Prism, and IRRAflow equipment. Gross margin also improved to 62% from 60%.
• Management raised the priority of commercial readiness after partner regulatory updates suggested potentially faster paths to Phase III enrollment and approval. ClearPoint expects 10–15 partner trials to enroll patients over the next 18 months and is expanding clinical support internationally.
• The company took possession of its 30,000-square-foot CAL preclinical facility and signed its first multimillion-dollar GLP services statement of work, expected to be completed in the first half of 2027. Management believes the facility could eventually support more than $60 million in annual revenue versus roughly $8 million of prior capacity.
• ClearPoint reduced its 2026 revenue guidance to $48 million–$52 million as it shifts spending toward clinical support, regulatory expansion, CAL equipment, focused ultrasound, robotics, and Harmony software rather than traditional sales expansion. Cash declined to $29.4 million at June 30 after $15 million of operating cash burn through the first half, although management expects burn to decrease in the second half.
• Management estimates high-teens to approximately 20% revenue growth in 2027, with upside from CAL utilization, potential commercial approvals, and stocking orders from pharmaceutical partners. Commercial procedures could generate approximately $12,000–$15,000 per patient on average, with certain programs such as uniQure’s estimated at $15,000–$25,000.

ClearPoint Neuro Stock Down 16.3%

Shares of CLPT opened at $12.88 on Wednesday. The firm has a market capitalization of $386.27 million, a price-to-earnings ratio of -12.75 and a beta of 1.24. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79. The business’s fifty day moving average price is $15.48 and its two-hundred day moving average price is $13.04. ClearPoint Neuro has a 52 week low of $8.27 and a 52 week high of $30.10.

Insider Transactions at ClearPoint Neuro

In other news, CEO Joseph Burnett sold 20,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $19.38, for a total transaction of $387,600.00. Following the completion of the sale, the chief executive officer owned 116,842 shares in the company, valued at $2,264,397.96. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Timothy T. Richards sold 5,415 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $12.17, for a total value of $65,900.55. Following the transaction, the director directly owned 87,198 shares in the company, valued at $1,061,199.66. This trade represents a 5.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 108,349 shares of company stock worth $1,796,118. Insiders own 6.94% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of ClearPoint Neuro by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,497,637 shares of the company’s stock worth $32,634,000 after buying an additional 22,517 shares during the period. Millennium Management LLC boosted its stake in ClearPoint Neuro by 156.3% in the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after acquiring an additional 452,043 shares during the last quarter. State Street Corp grew its holdings in ClearPoint Neuro by 30.1% during the 4th quarter. State Street Corp now owns 628,061 shares of the company’s stock worth $8,592,000 after acquiring an additional 145,411 shares during the period. FirstWave Capital Management LLC bought a new stake in shares of ClearPoint Neuro during the 4th quarter valued at $4,971,000. Finally, UBS Group AG lifted its stake in shares of ClearPoint Neuro by 132.1% in the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock valued at $7,860,000 after purchasing an additional 205,295 shares during the period. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on CLPT. B. Riley Financial boosted their target price on ClearPoint Neuro from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Lake Street Capital set a $25.00 price objective on ClearPoint Neuro in a research note on Tuesday. Stifel Nicolaus set a $22.00 target price on ClearPoint Neuro in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $25.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.